Phase 4 N=26 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Phase 4 N=12 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
Chronic Fatigue Syndrome
Primary: Change in Fatigue Impact Scale at 6 Weeks — -32.6; -1.5 units on a scale — p=< 0.05
Phase 3 N=60 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome
Fatigue Syndrome, Chronic
Primary: Change From Baseline in Multidimensional Fatigue Inventory (MFI)--General Fatigue Subscale Score — -3.3; -1.8 units on a scale — p=0.23
N/A N=300 Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
Chronic Fatigue Syndrome
Primary: Changes in Frequency and Severity of CDC-based CFS Symptoms — 0.29; 0.12; 0.49; 0.05 Units on a scale
N/A N=47 Integrative Medicine Consultation for Patients With Pain or Fatigue
Pain · Fatigue
Primary: Short Form 36 (SF-36) Physical Component Summary (PCS) — 36.2; 39.0 Scores on a scale — p=0.487
N/A N=52 Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
Chronic Fatigue Syndrome
Primary: Cardiopulmonary Exercise Test (CPET) - ATVO2rel — 16.0; 10.6 mL/kg/min
Phase 3 N=8 ACTH for Fatigue in Multiple Sclerosis Patients
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
N/A N=590 Fatigue Management Programs for People With MS
Multiple Sclerosis
Primary: Change From Baseline in Fatigue Levels — 50.98; 56.88; 57.87 score on a scale
Phase 4 N=155 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment
Q Fever · Fatigue Syndrome, Chronic · Coxiella Infection
Primary: Checklist Individual Strength (CIS) — 31.6; 40.8; 37.8 score on a scale
N/A N=21 Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
Multiple Sclerosis · Fatigue
Primary: Intervention Acceptability — 4.36; 4.64; 4.68 Units on a scale
Phase 4 N=336 Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
Multiple Sclerosis
Primary: Change in the Modified Fatigue Impact Scale (MFIS) Score — -15.2; -16.0; -17.3 score on a scale — p=0.3451
Phase 3 N=141 Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Fatigue in Multiple Sclerosis
Primary: Modified Fatigue Impact Scale (MFIS) Score — 40.6; 41.3; 39.0; 38.6 score on a scale
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
N/A N=181 Teleconference Fatigue Management for People With Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in Subscale Scores of the Fatigue Impact Scale — -3.74; -1.22; -4.24; -1.11 units on a scale — p=<0.05
Phase 4 N=13 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
Chronic Fatigue Syndrome
Primary: EEG Slow Wave Activity During Sleep — 0.00002653; 0.00002257 uV^2/Hz
N/A N=35 Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Change in Average Fatigue Severity Scale (FSS) Score — 45.824; 46.714 score on a scale
N/A N=25 Apollo Device for Fatigue in Systemic Sclerosis
Systemic Sclerosis · Fatigue · Raynaud Phenomenon
Primary: Change in PROMIS® Item Bank v1.0 - Fatigue - Short Form 13a (FACIT-Fatigue) at 4 Weeks (End-of-Study) Compared to Baseline — -7.0; 62.5 T-score — p=<0.001
N/A N=20 Telephone-Delivered Exercise for Multiple Sclerosis Fatigue
Multiple Sclerosis · Fatigue · Physical Activity
Primary: Daily Average Fatigue Intensity Score — 3.9; 4.4; 3.2; 2.3 units on a scale
Phase 2 N=262 Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score — -1.5; -1.8; -1.9 units on a scale
Phase 2 N=45 MitoQ for Fatigue in Multiple Sclerosis (MS)
Multiple Sclerosis · Fatigue
Primary: Modified Fatigue Inventory Scale (MFIS) — 46.5; 55.2; 54.3; 45.1 units on a scale — p=0.9489
Phase 2 N=15 A Study of Oxidative Pathways in MS Fatigue
Progressive Multiple Sclerosis · Fatigue
Primary: Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine. — 12; 6 adverse events
Phase 4 N=55 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue
Fibromyalgia, Primary
Primary: Brief Fatigue Inventory — 2.86; 4.29 units on a scale — p=<0.05
Phase 2 N=8 A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue
Fatigue
Primary: Percentage Change in Self-reported Fatigue Visual Analog Scale (VAS) Scale — -21.0; -12.6 Percentage change
N/A N=50 SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Sarcoidosis · Fatigue
Primary: Proportion of Participants Recruited — 25; 25 Participants
N/A N=74 Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue
Post Covid-19 Patients
Primary: Fatigue Assessment Scale (FAS) — 31.32; 28.42; 14.90; 15.3 Total score (1 to 5 point scale)
Early Phase 1 N=64 Muscadine Grape Extract to Improve Fatigue
Fatigue
Primary: Patient Reported Outcomes Measurement System (PROMIS) Fatigue 7a Questionnaire — -6.6; -5.4 score on a scale
Phase 2 N=12 A Rehabilitation Therapy for Post-stroke Fatigue
Stroke
Primary: Feasibility of Recruitment Process — 120; 49; 20; 12 participants
N/A N=18 Vagal Nerve Stimulation for Post COVID Fatigue
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Phase 2 N=19 Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672